Security Investigation
Hims & Hers Health, Inc. (NYSE: HIMS)
60 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS).
Hims & Hers and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims, disclosing that the Company had “failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk,” and that “the ‘semaglutide’ active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies” may contain “unsafe and illicit foreign ingredients.”
On this news, the price of Hims’ shares fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume.
If you purchased securities of Hims and would like to discuss your legal rights and how the case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The first-filed case is Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315. A subsequent case, Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321, expanded the class period.